Key Takeaways RHHBY's 1H25 sales rose 7% to CHF 30.9B, led by 10% growth in the Pharmaceuticals division.Top five drugs drove CHF 10.6B in sales, offsetting declines from biosimilar-hit legacy products. Core EPS rose 12% to CHF 11.08, with profit aided by strong sales and effective cost management.Swiss pharma giant Roche Holding AG ((RHHBY) reported sales of CHF 30.9 billion for the first half of 2025, up 4% year over year driven by the strong demand of drugs. Sales were up 7% at constant exchange rates (C ...